MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
Year: 2010
Type: conference-paper
Study design: Clinical Trial
Abstract: The benefit of bevacizumab (Bv) has been shown in different tumors including colorectal cancer, renal cancer, pulmonary non-small cell cancer and also breast cancer. However to date, there is no established test evaluating the angiogenic status of a patient and monitoring the effects of anti-angiogenic treatments. Tumor angiogenesis is the result of a balance between multiple pro- and anti¬angiogenic molecules. There is very little published clinical data exploring the impact of the anti-angiogenic therapy on the different angiogenesis-related molecules and the potential role of these molecules as prognostic or predictive factors.
Source: SERVAL (Université de Lausanne)
Authors: Zaman, K., Rochlitz, C., Ruhstaller, T., Thürlimann, B., Aebi, S., Von Moos, R., Mamot, C., Gabriel, N., Rossier-Pansier, L., Stupp, R., Crowe, S., Ruegg, C.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funder: Oncosuisse
OpenAlex ID: W6992876501